Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 13;137:106826. doi: 10.1016/j.vph.2020.106826

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Bradykinin signaling after SARS-CoV2 infection in pulmonary arterioles. Recent, high profile publications in eLife [4,5] have revealed that changes in the renin-angiotensin-aldosterone system after SARS-CoV2 infection could predispose bradykinin storms. Given that bradykinin and its metabolites are well-known inducers of endothelium-dependent vasodilation, vascular permeability, and pain via the activation of the G protein-coupled receptors B1 and B2, this signaling could be a novel therapeutic target in the treatment of COVID-19, including lung edema, cardiovascular dysfunction, and thromboembolism.